Complete Genomics(CG)-Shenzhen BGI deal gets blessing from U.S. authority

On December 28, 2012, the federal Committee on Foreign Investment in the United States cleared the way for BGI's acquisition of Complete Genomics (CG) (see the October 4, 2012 CHBP). The deal made news headlines after Illumina put in a competitive bid (see the November 22, 2012 CHBP) and a number of...

This research is archived and therefore no longer available. For further assistance please contact your Customer Success Manager or email ClientEngagementTeam@luxresearchinc.com. Thank you!

Related Research

PacBio acquires Omniome in deal worth $800 million, expanding its DNA sequencing capabilities

News Commentary | August 02, 2021

PacBio specializes in long‑read DNA sequencing, which provides insights on genomic variants including immunology, rare diseases, and microbiology. The company seeks to complement its service by integrating Omniome's short‑read sequencing (SRS) platform, which can be utilized for cancer screening, ... Not part of subscription

Illumina hit with further European Commission antitrust investigations over $8 billion bid for Grail

News Commentary | August 02, 2021

Grail, originally a spinoff of Illumina, develops early‑detection cancer diagnostics using blood samples, which the genomics company seeks to add back into its biotech arsenal. However, both the European Commission and the U.S. Federal Trade Commission argue that the takeover could harm competing ... Not part of subscription

Sequoia's new fund structure is good deal for investors; impact for entrepreneurs or corporate innovators is TBD – but likely not large

News Commentary | October 26, 2021

Famed venture firm Sequoia Capital is reorganizing to have one open‑ended parent "Sequoia Fund" over a variety of subfunds, some of which will remain typical closed‑ended venture funds while others invest in public markets or assets like crypto or pursue new models like registered investment ... To read more, click here.